Literature DB >> 24521951

Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels?

Jennifer H Huang1, Rachel Sunstrom2, Myrna Y Munar3, Ganesh Cherala3, Arthur Legg4, Ali J Olyeai3, Stephen M Langley2.   

Abstract

OBJECTIVES: Perioperative antibiotics have decreased-but not eradicated-postoperative infections. In patients undergoing cardiac surgery with cardiopulmonary bypass, the dilutional effect of the priming and any additional volume given during the procedure may lead to subtherapeutic antibiotic levels. Our aim was to determine if children undergoing cardiac surgery with cardiopulmonary bypass receive perioperative antibiotics at subtherapeutic levels.
METHODS: Using published pharmacokinetic data on cefuroxime, we developed a computer simulation model to generate a nomogram predicting patients at risk for subtherapeutic cefuroxime levels based on time from initial dosing and additional volume given.
RESULTS: A computer-generated 1-compartment pharmacokinetic model was created to predict cefuroxime plasma levels over time for patients of all weights and additional volumes given for both a 25- and 50-mg/kg intravenous dose. For example, following a 25-mg/kg dose, a patient receiving an additional volume of 275 mL/kg is predicted to be subtherapeutic (<16 mg/L=4×minimum inhibitory concentration) at 4 hours. Our nomogram predicts all patients will be subtherapeutic at 8 hours, consistent with general pediatrics dosing schemes. Following a 50-mg/kg dose, levels are predicted to be subtherapeutic after an additional volume of 315 mL/kg at 5.5 hours.
CONCLUSIONS: Our model predicts which patients undergoing cardiac surgery with cardiopulmonary will have subtherapeutic cefuroxime levels. This nomogram enables providers to determine when to administer additional antibiotics in patients receiving large additional volumes during cardiac surgeries. This rational approach to perioperative antibiotic dosing may result in a reduction in postoperative infection in this vulnerable patient population.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24521951      PMCID: PMC4099311          DOI: 10.1016/j.jtcvs.2013.12.043

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

1.  Influence of cardiopulmonary bypass on cefuroxime plasma concentration and pharmacokinetics in patients undergoing coronary surgery.

Authors:  Fabiana Ferreira; Silvia Santos; Jorge Nascimento; Tânia Strabelli; Maria Carmona
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-26       Impact factor: 4.191

Review 2.  Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.

Authors:  Dale W Bratzler; Peter M Houck
Journal:  Am J Surg       Date:  2005-04       Impact factor: 2.565

3.  The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration.

Authors:  Fred H Edwards; Richard M Engelman; Peter Houck; David M Shahian; Charles R Bridges
Journal:  Ann Thorac Surg       Date:  2006-01       Impact factor: 4.330

4.  The effective period of preventive antibiotic action in experimental incisions and dermal lesions.

Authors:  J F Burke
Journal:  Surgery       Date:  1961-07       Impact factor: 3.982

5.  Plasma cefazolin levels during cardiovascular surgery: effects of cardiopulmonary bypass and profound hypothermic circulatory arrest.

Authors:  Anthony D Caffarelli; Jeff P Holden; Ellen Jo Baron; Harry J M Lemmens; Holly D'Souza; Vincent Yau; Cornelius Olcott; Bruce A Reitz; D Craig Miller; Pieter J A van der Starre
Journal:  J Thorac Cardiovasc Surg       Date:  2006-06       Impact factor: 5.209

6.  A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.

Authors:  Anders Viberg; Anders Lannergård; Anders Larsson; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

7.  Pectoralis major muscle flap for deep sternal wound infection in neonates.

Authors:  E Erez; M Katz; E Sharoni; Y Katz; A Leviav; B A Vidne; O Dagan
Journal:  Ann Thorac Surg       Date:  2000-02       Impact factor: 4.330

8.  Systemic availability of prophylactic cefuroxime in patients submitted to coronary artery bypass grafting with cardiopulmonary bypass.

Authors:  J W L Nascimento; M J C Carmona; T M V Strabelli; J O C Auler; S R C J Santos
Journal:  J Hosp Infect       Date:  2005-04       Impact factor: 3.926

9.  Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery.

Authors:  M C Nahata; D E Durrell; M E Ginn-Pease; D R King
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

10.  Pharmacokinetics of cefuroxime axetil suspension in infants and children.

Authors:  D A Powell; N C James; M J Ossi; M C Nahata; K H Donn
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.